Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4190007 | 0.93 | BACE1 (0.40) | IGF1RALOX15GABRA1GABRB2BACE1 | |
| SCHEMBL11300811 | 0.89 | IGF1R (0.35) | IGF1RALOX15GABRA1GABRB2BACE1 | |
| SCHEMBL3721174 | 0.86 | IGF1R (0.39) | IGF1RALOX15 | |
| SCHEMBL7758297 | 0.85 | BACE1 (0.34) | IGF1RALOX15GABRA1GABRB2BACE1 | |
| SCHEMBL7756328 | 0.83 | ALOX5 (0.35) | BACE1ALOX5BCHEADRB2ADRB1 | |
| SCHEMBL11296010 | 0.83 | ALDH1A1 (0.38) | ALOX15BACE1ALOX5CALM1 | |
| SCHEMBL27490340 | 0.82 | ADRB2 (0.38) | IGF1RALOX15GABRA1GABRB2BACE1 | |
| SCHEMBL7755087 | 0.82 | ADRB2 (0.35) | ALOX5ADRB2ADRB1ADRB3 | |
| SCHEMBL6473875 | 0.82 | GRIN2D (0.41) | ALOX15 | |
| SCHEMBL11295519 | 0.82 | HTR2B (0.39) | IGF1RALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2867199-A2 | STABLE COMPOSITIONS OF FESOTERODINE | Hetero Research Foundation (IN) | 2015-05-06 | — | — | EP | claimed |
| WO-2014006636-A2 | STABLE COMPOSITIONS OF FESOTERODINE | HETERO RESEARCH FOUNDATION (IN) | 2014-01-09 | — | — | WO | claimed |
| EP-2580203-A1 | PROCESS FOR THE PREPARATION OF 2 -HYDROXY- 4 -PHENYL -3, 4 -DIHYDRO-2H-CHROMEN- 6 -YL -METHANOL AND (R) - FESO - DEACYL | Chemi SPA (IT) | 2013-04-17 | — | — | EP | claimed |
| WO-2012098560-A2 | PROCESS FOR THE PREPARATION OF MUSCARINIC RECEPTOR ANTAGONIST | MSN LABORATORIES LIMITED (IN) | 2012-07-26 | — | — | WO | claimed |
| WO-2012025941-A2 | PROCESSES FOR THE PREPARATION OF FESOTERODINE | CADILA HEALTHCARE LIMITED (IN) | 2012-03-01 | — | — | WO | claimed |
| WO-2011154854-A1 | PROCESS FOR THE PREPARATION OF 2 -HYDROXY- 4 -PHENYL -3, 4 -DIHYDRO-2H-CHROMEN- 6 -YL -METHANOL AND (R) - FESO - DEACYL | CHEMI SPA (IT) | 2011-12-15 | — | — | WO | claimed |
| WO-2011141932-A2 | PROCESS FOR PREPARATION OF PHENOLIC MONOESTERS OF HYDROXYMETHYL PHENOLS | INTAS PHARMACEUTICALS LIMITED (IN) | 2011-11-17 | — | — | WO | claimed |
| WO-2009037569-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF FESOTERODINE | ACTAVIS GROUP PTC EHF (IS) | 2009-03-26 | — | — | WO | claimed |
| WO-2005012227-A2 | PROCESS FOR PREPARATION OF 2-(3-DIISOPROPYLAMINO-1-PHENYLPROPYL)-4-HYDROXYMETHYL-PHENOL, A METABOLITE OF TOLTERODINE | RANBAXY LABORATORIES LIMITED (IN) | 2005-02-10 | — | — | WO | claimed |
| US-20040186061-A1 | Novel derivatives of 3,3-diphenylpropylamines | SCHWARZ PHARMA AG | 2004-09-23 | — | — | US | claimed |
| US-6713464-B1 | ANTIMUSCARINIC AGENTS WITH SUPERIOR PHARMACOKINETICS | SCHWARZ PHARMA AG (DE) | 2004-03-30 | — | — | US | claimed |
| EP-1254890-A1 | Derivatives of 3,3-diphenylpropylamines | SCHWARZ PHARMA AG (DE) | 2002-11-06 | — | — | EP | claimed |
| EP-1230209-A2 | STABLE SALTS OF NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SCHWARZ PHARMA AG (DE) | 2002-08-14 | — | — | EP | claimed |
| US-20020094986-A1 | Combination treatment for depression, anxiety and psychosis | PFIZER INC | 2002-07-18 | — | — | US | claimed |
| EP-1077912-B1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SANOL ARZNEI SCHWARZ GMBH (DE) | 2002-07-03 | — | — | EP | claimed |
| WO-2001035957-A2 | — | — | 2001-05-25 | — | — | WO | claimed |
| WO-2001035957-A1 | STABLE SALTS OF NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SANOL ARZNEI SCHWARZ GMBH (DE) | 2001-05-25 | — | — | WO | claimed |
| WO-2017137955-A1 | NOVEL (R) AND RAC 3-(2-(ALLYLOXY)-5-METHYLPHENYL)-N,N-DIISOPROPYL-3- PHENYLPROPAN-1-AMINE AND ITS USE FOR SYNTHESIS OF (R) AND RAC-2-(3- (DIISOPROPYLAMINO)-1-PHENYLPROPYL)-4-(HYDROXYMETHYL)PHENOL | CELESTIS PHARMACEUTICALS PVT. LTD. (IN) | 2017-08-17 | — | — | WO | disclosed |
| EP-1077912-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SCHWARZ PHARMA AG (DE) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058478-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SCHWARZ PHARMA AG (DE) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186061-A1 | Novel derivatives of 3,3-diphenylpropylamines | ADRB3, ADRA1D, TNNC1 | IGF1R 2004/4885ALOX15 2393/4885GABRA1 1796/4885 |
| US-20020094986-A1 | Combination treatment for depression, anxiety and psychosis | HTR4, CHRNA4, GRM4 | IGF1R 2088/4885ALOX15 2495/4885GABRA1 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.